Company profile
MINERVA NEUROSCIENCES, INC.
NASDAQ:NERVBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| MIN-117 | phase2 | — | 1 | no active trials |
| ROLUPERIDONE HYDROCHLORIDE | phase1 | — | 3 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03072056 | phase1 | completed | 2017-01-09 | 2017-07-07 | Minerva Neurosciences | A Pharmacokinetic Study of MIN-101 and Its Metabolites in Healthy Subjects to Compare MIN-101 in Poor and Extensive Metabolizers |
| NCT03038646 | phase1 | completed | 2016-11-30 | 2017-04-20 | Minerva Neurosciences | A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Healthy Subjects |
| NCT03446846 | phase2 | completed | 2018-03-30 | 2019-11-21 | Minerva Neurosciences | A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder |
| NCT06107803 | phase1 | completed | 2023-10-13 | 2024-01-12 | Minerva Neurosciences | A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia |
| NCT02232529 | phase1 | completed | 2014-09-01 | 2015-02-01 | Minerva Neurosciences | Pharmacokinetic Study of MIN-101 in Healthy Subjects |
FDA applications (0)
No records yet.